Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.
Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the Israeli Ministry of Health has approved a Phase I/II clinical trial for Allocetra™, aimed at patients with advanced solid tumors. This trial follows positive preclinical studies with Yale Cancer Center indicating significant survival benefits when Allocetra™ was combined with PD1 checkpoint inhibition. The trial will enroll up to 48 patients, evaluating safety, tolerability, and preliminary efficacy of Allocetra™ alone and combined with anti-PD1 therapy. The study addresses a significant unmet medical need in cancer treatment.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced a Notice of Allowance from the U.S. Patent and Trademark Office for patent application number 16/594,463 regarding its sepsis treatment, Allocetra™. This patent will extend IP protection until at least 2036, enhancing its commercial potential in a largely underserved multi-billion-dollar market. The ongoing Phase II trial of Allocetra™ aims to assess safety and efficacy, with interim results anticipated in Q1 2023 and top-line data expected in Q3 2023.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has initiated its first Phase I/II clinical trial for Allocetra™, an innovative macrophage reprogramming therapy targeting peritoneal metastases in solid cancer patients. This trial, supported by Sheba Medical Center, aims to evaluate the safety and preliminary efficacy of Allocetra™ combined with standard chemotherapy. Peritoneal cancer has a low survival rate, making new treatments critical. The trial will assess dose escalation and monitor adverse events, with the potential to redefine treatment options for patients with limited responses to existing therapies.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has announced a corporate update presentation at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 1:00 PM ET. The company focuses on macrophage reprogramming immunotherapy, particularly its product Allocetra™, designed to treat diseases like sepsis and solid tumors. A webcast of the presentation will be accessible for 90 days. Allocetra™ aims to restore macrophage homeostasis, addressing significant medical needs by reprogramming non-homeostatic macrophages.
Enlivex Therapeutics announced the Israeli Ministry of Health's authorization to begin a Phase I/II clinical trial for Allocetra™ combined with chemotherapy in patients with peritoneal metastases from solid tumors. This trial responds to the urgent need for new treatments for this terminal condition, where current therapies offer limited survival benefits. Enlivex aims to enroll approximately 12 patients, with the primary endpoint focused on safety and adverse events. The study is set to initiate in Q3 2022, following promising preclinical data suggesting Allocetra™ could enhance cancer treatment efficacy.
Enlivex Therapeutics Ltd. has announced promising preclinical findings regarding the use of Allocetra™ in combination with anti-PD1 checkpoint inhibitors for treating ovarian cancer. Conducted in collaboration with Yale Cancer Center, the study showed a survival probability of up to 50% and an 83% increase in survival duration compared to untreated groups. This highlights Allocetra’s potential to enhance checkpoint inhibitor efficacy in difficult-to-treat cancers. The results will be presented at the ASCO Annual Meeting from June 3-7, 2022.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has been awarded a grant of approximately $1.2 million from the Israel Innovation Authority for its ongoing sepsis clinical trial in 2022. This brings the total non-dilutive funding from the IIA to about $7.8 million since the inception of their partnership. Enlivex is currently recruiting patients for its Phase IIb trial of AllocetraTM, aimed at treating organ dysfunction associated with sepsis. AllocetraTM is designed to reprogram macrophages, potentially addressing unmet medical needs in critical conditions.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) appointed Roger J. Pomerantz, M.D., as Vice Chairman of its Board of Directors. Dr. Pomerantz is a seasoned pharmaceutical expert with a history of leading significant business developments, including over 150 transactions at Merck & Co. and roles at Johnson & Johnson and Seres Therapeutics. He expressed excitement about Enlivex's Allocetra cell therapy, which aims to restore macrophage function in diseases like sepsis and solid tumors. The company anticipates a cash runway into Q3 2024, positioning it well for future growth.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in the H.C. Wainwright Global Investment Conference from May 23–26, 2022. The company's presentation will be pre-recorded and accessible throughout the event. Enlivex is developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to combat diseases such as sepsis and solid tumors. Allocetra™ targets non-homeostatic macrophages that worsen these conditions, potentially offering a new immunotherapeutic approach for serious medical needs.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in the Allogeneic Cell Therapies Summit 2022 and the 20th Biomed Israel Conference. Presentations include topics on their innovative therapy, Allocetra™, targeting solid tumors and cytokine storms linked to sepsis and COVID-19. Key details include a presentation on 'Next Generation Allogeneic Modality for Solid Tumors' on May 10, 2022, and two presentations at the Biomed Israel Conference on May 10 and 12. The focus is on the therapeutic potential of Allocetra™ in treating severe conditions.